# Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Canonical URL: https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-data-at-the-2025-ash-annual-meeting-from-its-myeloproliferative-neoplasm-mpn-programs
Ticker: PRLD
Company: Prelude Therapeutics
Source: Prelude Therapeutics
Published: 2025-12-06 16:00 EST
Original Source URL: https://investors.preludetx.com
## Summary

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR)

## Article Body
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR)
## Recent Company News
- 2026-05-12 11:01 EST — [Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Prelude Therapeutics
- 2026-04-20 10:30 EST — [Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering) — Source: Prelude Therapeutics
- 2026-04-20 10:00 EST — [Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026) — Source: Prelude Therapeutics
- 2026-04-15 11:30 EST — [Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer) — Source: Prelude Therapeutics
- 2026-03-17 20:31 EST — [Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-acceptance-of-preclinical-abstract-for-prt13722-a-first-in-class-oral-kat6a-selective-degrader-at-the-2026-aacr-annual-meeting) — Source: Prelude Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)